An antibody treatment studied for some stomach cancers
Bemarituzumab
An antibody given by drip for certain stomach cancers that carry a specific marker, which works by targeting that marker on the cancer cells.
What is Bemarituzumab?
Bemarituzumab is a specialist antibody medicine given by drip into a vein for certain stomach (gastric) cancers that carry a particular marker called FGFR2b. It works by attaching to this marker on the cancer cells and interfering with a signal the cancer uses to grow. It is used within cancer services, often alongside chemotherapy. Its most distinctive risk is eye problems, particularly affecting the clear front of the eye (the cornea), so regular eye checks are needed, and it can also cause reactions during the infusion. It is given and monitored by specialist cancer teams.
Education and reference only. This is a plain-language guide to Bemarituzumab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Bemarituzumab is a type of medicine called a monoclonal antibody, designed to recognise a specific marker called FGFR2b that is found on some stomach cancer cells. It is used for gastric cancers that test positive for this marker, often together with chemotherapy. It is given as an infusion (a drip) into a vein within a cancer service. Because it is a targeted treatment, people's tumours are tested for the marker first to see whether the medicine is likely to help.
How it works
Some stomach cancers carry extra amounts of a receptor called FGFR2b on their surface, which the cancer uses as a growth signal. Bemarituzumab is an antibody that binds to this receptor, blocking the growth signal and flagging the cancer cells to the immune system. By interrupting this pathway, it aims to slow the cancer's growth. Because the cornea, the clear front layer of the eye, also relies on related signals to stay healthy, blocking this pathway is thought to be why eye and corneal problems are a particular concern with this medicine.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist antibody medicine, given by drip, studied for certain stomach (gastric) cancers that carry a particular marker called FGFR2b, used within cancer services and trials.
Practical use
How to take Bemarituzumab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as a drip into a vein in a cancer unit, on a schedule set by your specialist team.
- Attend the regular eye checks arranged for you, as this medicine can affect the eyes.
- Use any lubricating eye drops as advised, and report new eye symptoms such as soreness, blurring or light sensitivity promptly.
- Tell the team straight away if you feel unwell during the infusion, such as flushing, fever or chills.
- It is often given alongside chemotherapy, so follow the full treatment plan you are given.
Weighing it up
Advantages & disadvantages of Bemarituzumab
Advantages
- Targets a specific marker (FGFR2b) on certain stomach cancer cells, aiming to slow the cancer's growth.
- Can be combined with chemotherapy as part of a treatment plan.
- Used as a targeted treatment, so the cancer is tested first to see whether it is likely to help.
Disadvantages
- Can cause eye problems, particularly affecting the cornea, needing regular eye checks.
- Can cause reactions during the infusion, so it is given carefully with monitoring.
- Only suitable for cancers that test positive for the FGFR2b marker, and given only in specialist services.
Practical use
Good to know
The most distinctive thing to know about bemarituzumab is that it can cause eye problems, especially affecting the cornea, the clear front of the eye. This can show up as dry, gritty or sore eyes, blurred vision or sensitivity to light, so regular eye examinations are arranged and any new eye symptoms should be reported promptly. Lubricating eye drops are often advised, and the team may pause or stop the medicine if eye changes are significant. Reactions during the infusion, such as flushing, fever or chills, can also happen, so the first doses are given carefully with monitoring. It is a targeted treatment, so the cancer is tested for the FGFR2b marker first, and it is given and supervised entirely within specialist cancer services.
Who should not take it / use with caution
- People who have had a serious allergic or infusion reaction to bemarituzumab should not be given it.
- It is used with great caution, or avoided, in people with significant existing eye or corneal problems.
- It is only used for cancers that test positive for the FGFR2b marker.
- It is used in pregnancy only if clearly necessary; discuss contraception and family planning with your cancer team.
Monitoring
- Regular eye examinations to check for corneal and other eye changes.
- Watching for infusion reactions, especially with the first doses.
- Reviewing how the cancer is responding and checking for other side effects over time.
Side effects
- Eye problems such as dry, gritty or sore eyes, blurred vision or light sensitivity, particularly affecting the cornea.
- Reactions during the infusion, such as flushing, fever or chills.
- Mouth soreness, nausea or tiredness, which can also be linked to chemotherapy given alongside.
- Less commonly, more serious eye or infusion reactions, which need prompt attention.
Key interactions
- It is often given with chemotherapy, and the team plans the combination and watches for added side effects.
- Tell your cancer team about all your medicines, including eye drops and over-the-counter products.
- There are few well-established routine medicine interactions, but a full medicines list is still important.
Available as: A solution given by infusion (drip) into a vein.
Answers
Bemarituzumab: frequently asked questions
What is bemarituzumab used for?
It is a targeted antibody given by drip for certain stomach (gastric) cancers that carry a particular marker called FGFR2b, often used alongside chemotherapy.
How does it work?
It binds to the FGFR2b marker on the cancer cells and blocks a growth signal the cancer uses, aiming to slow its growth.
Why are eye checks needed?
It can cause eye problems, especially affecting the cornea at the front of the eye, so regular eye examinations are arranged and new eye symptoms should be reported promptly.
Can it cause reactions during the drip?
Yes. Reactions such as flushing, fever or chills can happen during the infusion, so it is given carefully with monitoring, especially for the first doses.
Is it suitable for everyone with stomach cancer?
No. It is only used for cancers that test positive for the FGFR2b marker, so the tumour is tested first to see whether the medicine is likely to help.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.